Rationales for treating IgA nephropathies

Renal Failure

Volumn 22, Issue 1, 2000, Pages 1-16

  Wardle, E Nigel ^a  

^a NONE   (United Kingdom)

Author keywords

Angiotensin II; Complement; Eicosanoids; IgA glomerulonephritis; PAF; Reactive oxygen species; Renal interstitial fibrosis

Indexed keywords

ANGIOTENSIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN DERIVATIVE; ICOSANOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT; THROMBOXANE RECEPTOR BLOCKING AGENT;

ARTICLE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MESANGIUM CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TONSILLECTOMY; TREATMENT INDICATION;

FISH OILS; GLOMERULONEPHRITIS, IGA; HUMANS; TONSILLECTOMY;

EID: 0034054863     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-100100846     Document Type: Article

References (116)

1. Suzuki S, Nakatomi Y, Odani S, Sato H, Gejyo P, Arakawa M: Circulating IgA, IgG and IgM class antibody against Hemophilus parainfluenzae antigens in patients with IgA nephropathy. Clin Exp Immunology 104:306-311, 1996.
2. Ibels LS, Gyory AZ, Caterson RJ, Pollock A, Mahony JF, Waugh DA, Roger SD, Coulshed S: Natural history and factors of importance in the progression of renal impairment. Kid Int 52,suppl.61:S67-S70, 1997.
3. Haas M: Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 29:829-842, 1997.
4. Freese P, Norden G, Nyberg G: Morphologic high risk factors in IgA nephropathy. Nephron 79:420-425, 1998.
5. Ruggementi P, Gaspari P, Perna A, Remuzzi G: Study of spot morning urine protein/creatinine ratio, glomerular filtration rate and end stage renal failure in patients without diabetes. Brit Med J 316:504-509, 1998.
6. Reichert LJ, Koene RA, Wetzels JF: Urinary excretion of beta - 2 microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Amer Soc Nephrol 6:1666-1669, 1995.
7. Yokoyama H, Takeda M, Wada T: Intraglomerular expression of MHC classII and Ki-67 antigens and serum ∼-IFN in IgA nephropathy. Nephron 62:169-175, 1992.
8. Naito T, Nitta K, Ozu H, Tsuchiya K, Matsugami K, Honda K, Yumura W, Nikei H: Clinical assessment of the significance of PDGF in patients with immunoglobulin-A nephropathy. J Lab Clin Med 130:63-68, 1997.
9. Ranieri E, Gesualdo L, Petrarulo F, Schena FP: Urinary Il-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50:1990-2001, 1996.
10. Hotta O, Taguma Y, Ooyama M, Yusa N, Nagura H: Analysis of CD14+ cells and CD56+ cells in urine using flow cytometry: a useful tool for monitoring disease activity of IgA nephropathy. Clin Nephrology 39:289-294, 1993.
11. Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R: PDGF and TGFβ contribute to the natural course of human IgA glomerulonephritis. Kidney Int 48:1530-1541, 1995.
12. Emancipator SN, Lamm ME: IgA nephopathy:pathogenesis of the most common form of glomerulonephritis. Lab Inv 60:168-183, 1989.
13. Endo Y: IgA nephropathy:human disease and animal model. Renal Failure 19:347-371, 1997.
14. Williams DG: Pathogenesis of idiopathic IgA nephropathy. Pediatr Nephrol 7:303-311, 1993.
15. Feehally J: IgA nephropathy - a disorder of IgA production? Quart J Med 90:387-390, 1997.
16. Gesualdo L, Emancipator SN, Kesselheim C, Lamm ME: Glomerular hemodynamic and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 42:106-114, 1992.
17. Coppo R, Amore A, Gianoglia B, Cacece G et al.: Angiotensin II local hyperreactivity on the progression of IgA nephropathy. Amer K Kidney Vhs 21:593-602, 1993.
18. Keen HL, Brando MW, Smith MJ, Shek EW, Hall JE: Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension 29:310-314, 1997.
19. Tomino Y: Complement system in IgA nephropathy. Tokai J Exp Clin Med 5:15-22, 1980.
20. Scheinman JI, Trachtman H, Lin C-Y, Langman CB, Chan JCM: IgA nephropathy: to treat or not to treat. Nephron 75:251-258, 1997.
21. Ibels LS, Gyory AZ, Caterson RJ, Pollock CA et al.: Recognition and management of IgA nephropathy. Drugs 55:73-83, 1998.
22. Kon V, Fogo A, Ichikawa I.: Bradykinin causes selective efferent arteriolar dilatation during angiotensin II converting enzyme inhibition. Kidney Int 44:545-550, 1993.
23. Maschio G, Alberti D, Janin G et al.: Effect of the ACE inhibitor benzepril on the progression of chronic renal insufficiency. New England J Med 334:939-945, 1996.
24. Nishimura M, Okamura M, Konishi Y et al.: Effect of treatment with ACE inhibitor of TGFβ gene expression in renal biopsy from patients with IgA nephropathy. J Amer Soc Nephrol 6:397 abs. 1995.
25. Benigni A, Corma D, Maffi R, Benedetti G, Zoja C, Remuzzi G: Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 54:353-359, 1998.
26. Holdaas H, Hartmann A, Berg K, Lund K, Fauchald P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transpl 13:3096-3102, 1998.
27. Schena P, Montenegro M, Scibittaro V: Meta-analysis of randomized controlled trials in patients with primary IgA nephropathy. Nephrol Dial Transplant 5 suppl 1:47-52, 1990.
28. Walker RG, Yu SH, Owen JE et al.: Treatment of mesangial mgA nephropathy with cyclophosphamidedipyridamole and warfarin. Clin Nephrology 34:103-108, 1990.
29. Andreoli SP, Bergstein JM: Treatment of severe IgA nephropathy in children. Ped Nephrol 3:248-251, 1989.
30. Goumenos D, Ahuja M, Shortland JR et al.: Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transpl 10:1173-1181, 1995.
31. Ballardie PW, Roberts ISD: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. Nephrol Dial Transplant 11(8): 1684 abs., 1996.
32. Schleimer RP: Effects of glucocorticoids in inflammatory cells relevant to their therapeutic applications in asthma. Amer Rev Reap Dis 141:S59-S69, 1990.
33. Almauri WY, Beyhum HN, Rahme AA, Rieder HJ: Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukocyte Biol 60:563072, 1996.
34. Reichert LJM, Koene RAP, Wetzels JFM: Acute hemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrol Dial Transplant 14:91-97, 1999.
35. Ayanlar Batuman O, Ferrero AP, Diaz A, Jiminez SA: Regulation of TGFβ1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest 88:1574-1580, 1991.
36. Almawai WY, Irani-Hakime N: (1998)The antiproliferative effect of glucocorticoids: is it related to induction of TGF? Nephrol Dial Transplant 13:2450-2452, 1998.
37. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S: Steroid therapy during the early stage of progressive IgA nephropathy. Nephron 72:237-242, 1996.
38. Waldo FB, Alexander R, Wyatt RJ, Kohaut EC: Alternate day prednisone therapy in children with IgA associated nephritis. Amer J Kidney Dis 13:55-60, 1989.
39. Pozzi C. Bolasco PG, Fogazzi GB, Andulli S, Altieri P, Ponticelli C: Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 353:883-887, 1999.
40. Ando Y, Moriyama T, Oka K, Takatsuji K, Miyazaki M et al.: Enhanced interstitial expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Nephrol Dial Transplant 14:1408-1417, 1999.
41. Diamond JR: Reactive oxygen species and progressive glomerular disease. Lab Invest 124:468-469, 1994.
42. Wardle EN: Antioxidants in the prevention of renal disease. Submitted.
43. Prior RL, Cao G: Antioxidant capacity and polyphenolic components of teas: implications for altering in viva antioxidant status. Proc Soc Exp Biol Med 220:255-261, 1999.
44. Wardle EN: Soyprotein diet therapy in renal disease. Nephron 78:328-331, 1998.
45. Wardle EN: Can pentoxifylline prevent renal disease? Renal Failure 20:437-440, 1998.
46. Isbrucker RA, Peterson TC: PDGF and pentoxifylline modulation of collagen synthesis by myofibroblasts. Tox Appl Pharm 149:120-126, 1998.
47. Kusakari C, Nose M, Takasaka T, Yuasa R et al.: Immunopathological features of palatine tonsil characteristic of IgA nepbropathy: IgAl localization in follicular dendritic cells. Clin Exp Immunology 95:42-48, 1994.
48. Quiding-Jarbrink M, Granstrom G, Nordstrom I, Holmgren K, Czerkinsky C: Induction of compartmentalized B cell responses in human tonsils. Infection Immunity 63:853-857, 1995.
49. Sato Y, Hotta O, Taguma Y, Takasaka T, Nose M: IgA nephropathy with poorly developed lymphoepithelial symbiosis of the palatine tonsils. Nephron 74:301-308, 1996.
50. Tomino Y, Yagame M, Suga T et al.: Detection of viral antigens in patients with IgA nephropathy. Japan J Med 28:159-164, 1989.
51. Babarak D, Dueymes M, Vperricbot R, Basset C et al.: Aberrant glycosylation of IgA from patients with IgA nephropathy. Glycoconjugate Journal 13:505-511, 1996.
52. Leung JC, Poon PY, Lai KN: Increased sialylation of polymeric IgAl: mechanisms of selective glomerular deposition in IgA nephropathy. J Lab Clin Med 133:152-160, 1999.
53. Wen-Guang Z, Ting-Fang W, Yang Y, Nin L: Chronic tonsillitis and IgA nephropathy. Chinese Med 106:770-777, 1993.
54. Iino Y, Ambe K, Kato Y et al.: Chronic tinsillitis and IgA nephropathy. Acta Otolaryngol suppl 508:29-35, 1993.
55. Rasche FM, Schwarz A, Keller F: Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrology 51:147-152, 1999.
56. Remuzzi G, Imberti L, Ressini M et al.: Increased glomerular thromboxane synthesis as a cause of proteinuria in experimental nephrosis. J Clin Invest 75:94-101, 1985.
57. Wilcox CS, Welch WJ, Snellen H: Thromboxane mediates renal hemodynamic response to infused angiotensin II Kidney Int 40:1090-1097, 1991.
58. Remuzzi G, Fitzgerald GA, Patrono C: Thromboxane synthesis and action within the kidney. Kidney Int 41:1483-1493, 1992.
59. Badr KF, DeBoer DK, Takahashi K et al.: Glomerular responses to PAF in the rat: role of thromboxane A2. Amer J Physiol 256:F35-F43, 1989.
60. Pinzani M, Laffi G, Meacci E, Lavilla G, Cominelli F, Gentilini P: Intrarenal thromboxane A2 generation reduces furosemide induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology 95:1081-1087, 1988.
61. Caughey GE, Pouliot M, Cleland KG, James HJ: Regulation of TNFa and Il-1 synthesis by thromboxane A2 in nonadherent human monocytes. J Immunology 158:351-358, 1997.
62. Reale M, Barbacane RC, Frydas S, Anogianakis G et al.: Human recombinant interleukin 1 induces thromboxane a2 release in polymorphonuclear leukocytes, macrophages and platelets: effect of Il-1 Ra. Mol.Cell Biochemistry 159:163-168, 1996.
63. Taniguchi Y, Yorioka N, Oda H, Yamakido M: Platelet derived growth factor, interleukin 1β, Il-6R and TNFa in IgA nephropathy. Nephron 74:652-660, 1996.
64. Studer RK, Negrete H, Craven PA, DeRubertis FR: Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGFβ bioactivity in mesangial cells. Kidney Int 48:422-430, 1995.
65. Bruggerman LA, Horikoshi S, Horrigan E. Ray P, Klotman PE: Thromboxane stimulates transcription of extracellular matrix protein. Amer J Physiol 261:F488-F494, 1991.
66. Kohan DE: Eicosanoids: potential regulators of extracellular matrix formation in the kidney. J Lab Clin Med 120:4-6, 1992.
67. Niwa T, Maeda K, Shibata M, Yamada K: Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. Clin Nephrology 30:276-281, 1988.
68. Wardle EN: Thromboxanes in glomerulonephritis and what about therapy? Amer J Therapeutics 6:111-114, 1999.
69. Endoh M, Kasham A, Yamauchi F. Yano N et al.: Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. Clin Nephrology 47:168-173, 1997.
70. Chan MK, Kim YO, Shin YS et al.: Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Amer J Kidney Dis 9:417-420, 1989.
71. Wardle EN: Dipyridamole in the nephritides. Amer J Therapeutics 5:107-109, 1998.
72. Hillis GS, Duthie LA, MacLeod AM: Dipyridamole inhibits human mesangial cell proliferation. Nephron 78:172-178, 1998.
73. Park CW, Kim YO, Shin YS et al.: Long term benefits of aspirin and dipyridamole and angiotensin converting enzyme inhibitor therapy in patients with IgA nephropathy. Kidney Int 51:969 abs, 1997.
74. Wardle EN: Phospholipid derived mediators and glomerulonephritis. Mediators of Inflammation 2:99-102, 1993.
75. Petric R, Ford-Hutchinson A: Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis. J Lipid Mediators Cell signaling 11:231-240, 1995.
76. O'Byrne PM, Israel E, Drazen JM: Antileukotrienes in the treatment of asthma. Annals Int Med 127:472-480, 1997.
77. Claesson HE, Dahlen SE: Antileukotrienes as novel antiasthmatic drugs. J Internal Med 245:205-227, 1999.
78. Ruiz-Ortega M, Bustos C, Plaza JJ, Egido J: Over expression of extra-cellular matrix proteins in renal tubulointerstitial cells by PAF stimulation. Nephrol Dial Transpl 13:886-892, 1998.
79. Grande JP, Donadio JV: n-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy. In: JM Kremer (ed.); Medicinal Fatty Acids in Inflammation. Birkhäuser Verlag, 1998, pp125-140.
80. Rifai A, Sakai H, Yagame H: Expression of 5 lipoxygenase and 5 lipoxygenase activating protein in glomerulonephritis. Kidney Int 39:595-599, 1993.
81. Spurney RF, Ruiz P, Albrightson CR, Pisetsky DS, Coffman TH: Fish oil feeding modulates leukotriene production in murine lupus nephritis. Prostaglandins 48:331-348, 1994.
82. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentaenoic acid. Clin Nephrology 31:128-131, 1989.
83. Donadio JV, Bergstrahl EJ, Offert KP et al.: A controlled trial of fish oil and IgA nephropathy. New Engl J Med 331:1194-1198, 1994.
84. Harats D, Dabach Y, Hollander G et al.: Fish oil ingestion in smokers and non-smokers enhances lipid peroxidation of plasma lipoproteins. Atherosclerosis 90:127-139, 1991.
85. Allard JP, Kurion R, Aghdassi E, Muggli R, Royall D: Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans. Lipids 32:535-541, 1997.
86. Chen LY, Lawson DL, Mehta JL: Reduction in neutrophil superoxide anion generation by n-3 PUFA. Thrombos Res 76:317-322, 1994.
87. Li Y, Ferrante A, Poulos A, Harvey DP: Neutrophil oxygen radical generation: synergistic effects of TNFa and mono/poluunsaturated fatty acids. J Clin Invest 97:1605-1609, 1996.
88. Fox PL, Salvatore HF: Serum factor that blocks the action of fish oils on endothelial cell production of PDGF is ceruloplasmin. Lab Invest 65:467-473, 1992.
89. Croft KD, Codde JP, Borden A, Vandongen R, Beilin LJ: Effect of diet fish oils in formation of leukotrienes B4/B5, thromboxane and PAF by rat leukocytes. Clin Exp Pharm Physiol 15:517-525, 1988.
90. Chakrabarti R, Hubbard NE, Lim D, Erickson K: Alteration of PAF induced signal transduction by n-3 fatty acids. Cell Immunol 175:76-84, 1997.
91. von Schacky C, Kiefl R, Jendraschak E, Kaminski EW: n-3 fatty acids and cysteinylleukotriene formation in humans. J Lab Clin Med 121:302-309, 1993.
92. Terano T, Salmon JA, Higgs GA, Moncada S: Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis. Biochem Pharpiacol 35:779-785, 1986.
93. Rychlik I, Tesar V, Jirsa M, Chabova V, Vernerova Z: Urinary eicosanoid excretion during fish oil treatment in IgA nephropathy. 8th International IgA Nephropathy Symposium, p71 abs. Leiden, May 1998.
94. Endres S, Ghorbani R, Kelley V, Georgilis J, Lonnemann G et al.: The effect of diet supplementation with n-3 polyunsaturated fatty acids on synthesis of Il-1 and TNFa by mononuclear cell. New England J Med 320:265-271, 1989.
95. Rothman D, Allen H, Herzog L et al.: Effect of unsaturated fatty acids on Il-1 beta production by monocytes. Cytokine 9:1008-1012, 1997.
96. Wardle EN: IgA nephropathy: to treat or not to treat? Nephron 79:221, 1998.
97. Romero F, Rodriguez-Iturbe B, Parra G et al.: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999.
98. Hauser IA, Renders E, Radeke H-H, Sterzel RB, Goppelt-Struebe H: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58-63, 1999.
99. Yuh-Chi Kuo: Chinese herbs as modulators of human mesangial cell proliferation. J Lab Clin Med 132:76-85, 1998.
100. Lin C-Y, Ku F-M, Kuo Y-E, Chen C-F et al.: Inhibition of activated human mesangial cell proliferation by the natural product of Cordyceps sinensis. J Lab Clin Med 133:55-63, 1999.
101. Wang ZQ, Liand KH, Pahl MV, Varizi ND: Effect of heparin on mesangial expression of matrix proteins. Neph D Tr 13:3052-3057, 1998.
102. Wardle EN: Heparins for proliferative nephritides? Nephron 73:515-519, 1996.
103. Piatti PM, Manti LD, Valsecchi G, Conti M et al.: Effects of low dose heparin infusion on arterial endothelin-1 release in humans. Circulation 94:2703-2707, 1996.
104. Largo R, Gomez-Garre D, Liu XH et al.: Endothelin-1 upregulation in the kidney of uninephrectomized SHR and its modification by the ACE inhibitor. Hypertension 29:1178-1185, 1997.
105. Yoshikawa N, Ito H: Combined therapy with prednisolone, azathioprine, heparin-warfarin and dipyridamole for pediatric patients with severe IgA nephropathy. Nephrol Dial Transplant 14(5):1097-1099, 1999.
106. Cade JR, DeQuasada AM, Shires DL, Levin DM et al.: The effect of long term high dose heparin treatment on the course of chronic proliferative glomerulonephritis. Nephron 8:67-80, 1971.
107. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH et al.: Antagonism of PDGF in glomerulonephritis by aptamers. Am J Path 154:159-179, 1999.
108. Floege J, Ostendorf T, Janjie N: Aptamers: novel tools for specific intervention studies. Nephrol Dial Transpl 14:1354-1357, 1999.
109. Chen A, Sheu L-F, Chou W-F, Tsai S-C et al.: Interleukin 1 receptor antagonist modulates the progression of spontaneously occurring IgA nephropathy in mice. Amer J Kid Dis 30:693-702, 1997.
110. Weiss RH, Ramirez A: TGFβ and angiotensin II induced mesangial matrix protein secretion is mediated by protein kinase. C Nephrol Dial Transplant 13:2804-2813, 1998.
111. Chen A, Sheu L-F, Shaio M-F, Huang T-H, Ding S-L, Lee W H: Antiidiotype antibody directly interferes with glomerular IgA immune complex deposition. Nephron 78:464-473, 1998.
112. Roccatello D, Mengozzi G, Ferro M, Cesano G et al.: Isosorbide 5mononitrate increases blood nitric oxide levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urine endothelin/cGMP ratio. Clin Nephrology 44:103-109, 1995.
113. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit Phar M et al.: High dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Annals Int Med 120:476-484, 1994.
114. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al.: Immunomodulation with low dose immunoglobulins for moderate IgA nephropathy and Henoch-Schonlein purpura. Nephron 69:327-334, 1995.
115. Miura M, Endoh M, Nomoto Y, Sakai H: Long term effect of urokinase therapy in IgA nephropathy. Clin Nephrology 32:209-216, 1989.
116. Frasca GM, Martello M, Sestigiani E, Caonova C, et al.: Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrol Dial Transpl 11:392, 1996.